Surovatamig

DRUG6 trials

Sponsors

AstraZeneca

Conditions

B-cell Non-Hodgkin LymphomaChronic Lymphocytic LeukaemiaChronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHVFollicular Lymphoma (FL)Large B-Cell Lymphoma (LBCL)Large B-cell LymphomaMantle-cell LymphomaPrimary Membranous Nephropathy

Phase 1

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

RecruitingNCT06564038

AstraZenecaB-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Large B-cell Lymphoma +2

Start: 2025-01-30End: 2029-06-11Target: 408Updated: 2026-05-14

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

RecruitingNCT07201558

AstraZenecaRheumatoid Arthritis, Systemic Lupus Erythematosus

Start: 2025-12-02End: 2028-06-27Target: 48Updated: 2026-02-17

Phase 2

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

RecruitingNCT06526793

AstraZenecaB-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)

Start: 2024-11-27End: 2029-06-14Target: 240Updated: 2026-02-25

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

RecruitingNCT07571746

AstraZenecaPrimary Membranous Nephropathy

Start: 2026-03-28End: 2029-10-15Target: 43Updated: 2026-05-06

Phase 3

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

RecruitingNCT06549595

AstraZenecaUntreated Follicular Lymphoma

Start: 2024-08-07End: 2031-11-26Target: 1018Updated: 2026-05-20

Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)

Not yet recruitingNCT07509151

AstraZenecaChronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV

Start: 2026-04-08End: 2033-08-29Target: 420Updated: 2026-04-03

Related Papers

SOUNDTRACK-B: A phase 2 single-arm study to evaluate the efficacy and safety of surovatamig (AZD0486) in relapsed or refractory B-cell non-Hodgkin lymphoma

Blood2025-11-03

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Blood2025-11-03

SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma

Blood2025-11-03

SOUNDTRACK-E: A phase 1/2, open-label, multicenter study to evaluate the safety and efficacy of AZD0486 monotherapy or combination therapy in patients with mature B-cell malignancies.

Journal of Clinical Oncology2025-05-28